Journal: Acta biomaterialia

Article Title: Biomimetic Modification of Poly(vinyl alcohol): Encouraging Endothelialization and Preventing Thrombosis with Antiplatelet Monotherapy

doi: 10.1016/j.actbio.2019.01.008

Figure Lengend Snippet: Graft samples were placed in an ex vivo shunt loop and exposed to whole, flowing blood for 60min. The arrow in the image indicates the direction of blood flow. A flow probe was included upstream to measure flow rate and a clamp was applied downstream to control the flow at a constant 100mL/min. Samples were tested without any antiplatelet therapies, with ASA monotherapy, or with DAPT.

Article Snippet: For ASA and DAPT trials, ASA (Bayer Healthcare) was given orally at 10 mg kg −1 at least 4hrs before the start of each experiment.

Techniques: Ex Vivo, Control

Journal: Acta biomaterialia

Article Title: Biomimetic Modification of Poly(vinyl alcohol): Encouraging Endothelialization and Preventing Thrombosis with Antiplatelet Monotherapy

doi: 10.1016/j.actbio.2019.01.008

Figure Lengend Snippet: Tubes of PVA with or without 30µg GFPGER/g PVA were tested in an ex vivo shunt model. Platelet accumulation was quantified over 60min exposure to whole blood (n=2 for collagen-ePTFE and N=5–6 for other groups). (A) In the absence of antiplatelet drugs, ePTFE devices accumulated significantly more platelets than GFPGER devices (LME ANOVA F2, 11=12.755 p=0.001, post hoc: ePTFE vs. plain PVA, p=1.0, ePTFE vs. GFPGER p=0.0035, plain PVA vs. GFPGER p=0.0834). (B) Under ASA monotherapy, ePTFE devices accumulated significantly more platelets than either PVA device. (LME ANOVA F2,12=13.86 p=8×10−4, post hoc: ePTFE vs. plain PVA p=0.0008, ePTFE vs. GFPGER p=0.0013, plain PVA vs. GFPGER p=1.0). (C) Under DAPT, plain PVA devices accumulated significantly fewer platelets than ePTFE devices (RMA F2,11=3.24 p=0.079, post hoc: ePTFE vs. plain PVA p=0.0310, ePTFE vs. GFPGER p=0.261, plain PVA vs. GFPGER p=0.681).

Article Snippet: For ASA and DAPT trials, ASA (Bayer Healthcare) was given orally at 10 mg kg −1 at least 4hrs before the start of each experiment.

Techniques: Ex Vivo

Journal: Acta biomaterialia

Article Title: Biomimetic Modification of Poly(vinyl alcohol): Encouraging Endothelialization and Preventing Thrombosis with Antiplatelet Monotherapy

doi: 10.1016/j.actbio.2019.01.008

Figure Lengend Snippet: Fibrin data were quantified and normalized per centimeter of axial length for all grafts at 60min. Results showed that (A) without antiplatelet therapy, ePTFE devices accumulated more fibrin than either PVA device (ANOVA F2, 11=5.57, p=0.02, post hoc: ePTFE vs. plain PVA, p=0.0168*, ePTFE vs. GFPGER p=0.180, plain PVA vs. GFPGER p=0.235). (B) No statistically significant differences were seen in fibrin deposition under ASA monotherapy (ANOVA F2,12=3.18, p=0.078). (C) ePTFE devices accumulated significantly more fibrin than either PVA device under DAPT (ANOVA F2,11=5.449, p=0.0227, post hoc: ePTFE vs. plain PVA, p=0.0444*, ePTFE vs. GFPGER p=0.019*, plain PVA vs. GFPGER p=0.768).

Article Snippet: For ASA and DAPT trials, ASA (Bayer Healthcare) was given orally at 10 mg kg −1 at least 4hrs before the start of each experiment.

Techniques: